Project description
Surgical visualisation solution sheds light on brain cancer
Surgery is most commonly used to remove cancer tumours. FluoGuide’s leading product – FG001 – is injected into the patient’s veins prior to surgery. It contains a fluorophore that binds to cancer cells expressing uPAR (highly expressed in virtually all human cancers). FluoGuide’s proprietary FG001 will revolutionise cancer surgery to improve the surgical outcome of more than 3 million cancer patients undergoing treatment every year. Glioblastoma multiforme (GBM) is the most aggressive type of cancer that begins within the brain, with a very poor prognosis. Surgery is currently extremely challenging as removing too much brain tissue can severely disable the patient. The EU-funded INSTAGLOW project will focus on accelerating the development of FG001 for GBM, enormously improving surgery for those patients.
Objective
Surgery is a cornerstone in treatment of early cancer, used in 45% of all patients, although cancer commonly recurs after surgery due to incomplete removal. The residual tumour not only leads to avoidable suffering and even dying of patients but also presents a huge financial burden for the healthcare system. As such, there is a major unmet need to accurately delineate tumour from healthy tissue, identify local metastases, and aid surgeons to precisely remove the entire tumour. FluoGuide will deliver FG001, a breakthrough, real-time, surgical visualisation solution that lights up cancer and improve surgical precision during removal surgery. FG001 is the first active targeting fluorescent tumour marker that targets uPAR, a receptor extensively expressed (95%) in a wide range (>50%) of solid tumours such as brain (glioblastoma; GBM), breast, colorectal, lung and head and neck cancers. FluoGuide’s proprietary FG001 will revolutionise cancer surgery to improve the surgical outcome of >3 million cancer patients undergoing surgery every year.
To realise this huge potential, FluoGuide is working on accelerating the development of FG001. Our initial focus is on GBM for which the prognosis is extremely poor with half of all patients dying within 14 months. Moreover, surgery is extremely challenging as removing too much brain tissue can severely disable the patient. FG001 can thus enormously improve surgery of GBM patients. The funding from EIC accelerator pilot will accelerate FG001’s clinical phase IIb/III study for GBM, and catapult FluoGuide to become a leader in cancer surgery guidance. We will generate revenues by 1) direct sales for compassionate use sales (2021) to showcase FG001, 2) direct sales in EU (2023), paid for via reimbursement by insurance companies and governments, and 3) roll-out to US and Asia (2025) through deals with large regional medical companies for local regulatory approval, and marketing and sales to ensure its full economic potential.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine surgery
- medical and health sciences clinical medicine oncology head and neck cancer
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3. - PRIORITY 'Societal challenges
See all projects funded under this programme -
H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-2 - SME instrument phase 2
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-EIC-SMEInst-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
2200 Copenhagen
Denmark
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.